Share on

Global Non-Invasive Prenatal Testing (NIPT) Market Size, Share, Trends, COVID-19 Impact & Growth Forecast Report – Segmented By Instruments (Ultrasound, NGS, PCR and Microarray), Method (FCMB and Cf-DNA), Application (Trisomy, Microdeletion, Genetics and Rh factor) and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Industry Analysis (2024 to 2029)

Published: March, 2023
ID: 2700
Pages: 176
Formats: report pdf report excel report power bi report ppt

Global Non-Invasive Prenatal Testing Market Size (2024 to 2029)

The global NIPT market size was valued at USD 2.6 bn in 2023. The global  non-invasive prenatal testing market is further estimated to grow at a CAGR of 15.6% during the forecast period and be worth USD 6.2 billion by 2029 from USD 3.01 billion in 2024.

Non-invasive prenatal testing (NIPT) is a famous prenatal screening test used to evaluate fetal chromosomal abnormalities, such as trisomy 21, trisomy 18, and trisomy 13. The success rate of NIPT is high, due to which the adoption of NIPT is increasing worldwide. NIPT believed as the safest choice for pregnant women as it just takes only a tiny blood sample for the procedures, unlike invasive surgeries. With the help of NIPT, parents can detect chromosomal abnormalities in the early stages of pregnancy and take the required actions.

Global Non-Invasive Prenatal Testing Market Drivers:

The growing number of pregnancies worldwide is one of the major factors propelling the non-invasive prenatal testing market growth. Women of the present generation are showing interest in having children at a later age. The preference among pregnant women towards non-invasive prenatal testing increases as this technique is safe, non-invasive, and gives high-accuracy results. To conduct non-invasive prenatal testing, a small blood sample would be taken from the pregnant woman's fetus and tested to evaluate the presence of chromosomal abnormalities. The number of pregnant cases grows worldwide, resulting in a growing number of NIPT procedures. People who get pregnant at a later age or with a history of genetic diseases are likely to have a high risk for fetal chromosomal abnormalities.

The rising support from the governments of several countries in favor of NIPT further fuels the NIPT market growth. The governments of some countries discussed with the insurance companies regarding the possibility of covering the costs of the NIPT under the insurance policies and recommended NIPT as a first-line screening test for chromosomal abnormalities. The governments of some countries have been offering to fund the R&D of NIPT and have taken several initiatives in favor of NIPT procedures. The favorable reimbursement policies promote the NIPT market growth. The procedures of NIPT have favorable reimbursement policies in the U.S., Canada, the UK, France, Italy, Spain, Germany, Japan, South Korea and others.

The growing awareness among healthcare professionals and the public regarding the advantages of NIPT boosts the growth rate of the non-invasive prenatal testing market. The growing number of initiatives by governmental organizations and patient advocacy groups to promote awareness among people regarding the benefits of NIPT, high costs associated with invasive procedures fuel the NIPT market growth. NIPT procedures are less risky and less invasive than traditional invasive testing procedures, and the affordability is higher than traditional testing methods. The growing adoption of technological advancements to enhance the efficacy of the NIPT and an increasing number of NIPT innovations support the market's growth rate.

Furthermore, the greater accuracy and sensitivity of NIPT compared to traditional prenatal testing methods, rising demand for early detection and diagnosis of fetal abnormalities to ensure proper medical care for the baby and the mother, increasing incidence of chromosomal disorders, such as Down syndrome, Turner syndrome, and Edwards syndrome and advancements in genomic technologies, such as next-generation sequencing (NGS) and microarray analysis promote the NIPT market growth. The growing adoption of cell-free DNA (cfDNA) analysis for NIPT allows for the detection of fetal chromosomal abnormalities using maternal blood samples, rising demand for personalized medicine and precision diagnostics, increasing healthcare expenditure and government initiatives to improve prenatal care and reducing infant mortality rates and rising availability of NIPT in emerging markets, such as China and India further support the growth rate of the NIPT market.

Global Non-Invasive Prenatal Testing Market Restraints:

Poor awareness levels among healthcare providers and patients regarding the advantages associated with NIPT are significant factors hampering the NIPT market growth. In addition, factors such as the high costs of NIPT, limited availability of NIPT in some of the developing countries, the presence of stringent regulations in some of the countries, and ethical concerns associated with the usage of NIPT in some of the countries are inhibiting the growth of the global non-invasive prenatal testing market. Furthermore, the availability of other prenatal screening and diagnostic tests hinders the market growth.

Impact of COVID-19 on the global non-invasive prenatal testing market:

COVID-19 had an unfavorable impact on the NIPT market during the initial days of the COVID-19 era. During the COVID-19 pandemic, priority has been given to attending the COVID-19 patients. As a result, less importance has been given to elective surgeries and kept non-invasive prenatal testing procedures on hold, reducing the demand for NIPT. In addition, the restrictions imposed by various governments to curb the spread of coronavirus, such as lockdowns, social distancing, and travel bans, resulted from the reduced usage of NIPT procedures. On the other hand, in the middle days of the COVID-19 era, the market participants of NIPT have reported an increase in the demand levels for the procedures; this can be attributed to the growing incidence of pregnancies during the COVID-19 pandemic and increasing concern among parents to have safe monitoring for their unborn child. Likewise, the NIPT has experienced a mixed impact of COVID-19 during the pandemic. However, the market is expected to register a healthy CAGR in the coming years.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2023 to 2029

Base Year

2023

Forecast Period

2024 to 2029

Segments Covered

By Instruments, Methods, Applications, End-User, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter’s Five Forces Analysis; Competitive Landscape, Analyst Overview of Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Key Market Players

G.E. Healthcare (U.S.), Koninklijke Philips N.V. (Netherlands), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pacific Biosciences of California, Inc. (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (U.S.) and Beijing Genomics Institute (China).

 

This research report on the global non-invasive prenatal testing market has been segmented and sub-segmented based on the instruments, methods, applications, end-users, and region.

Global Non-Invasive Prenatal Testing Market - By Instruments:

  • Ultrasound
  • NGS
  • PCR
  • Microarray

Based on instruments, the ultrasound segment had a leading share of the global non-invasive prenatal testing market in 2023 and the segment's domination during the forecast period. Ultrasound-based NIPT is one of the safe and most reliable to figure out the chromosomal abnormalities in a developing fetus. Therefore, the awareness of the benefits of ultrasound-based NIPT is majorly driving segmental growth. In addition, ultrasound is cost-effective compared to the other invasive treatment methods, which is anticipated to promote the segment's growth rate. Furthermore, the growing demand for prenatal screening and increasing adoption of technological developments to enhance the quality of ultrasound-based NIPT are expected to boost segmental growth.

The NGS segment held a considerable share of the global market in 2022 and is expected to grow at a healthy CAGR during the forecast period. Factors such as the ability of NGS to detect fetal abnormalities with high accuracy and specificity, the growing prevalence of genetic disorders, rising demand for early and accurate diagnosis of fetal abnormalities and advancements in NGS technology propel the segmental growth.

Global Non-Invasive Prenatal Testing Market - By Method:

  • FCMB
  • Cf-DNA

Based on the method, the cf-DNA segment accounted for a significant share of the global NIPT market in 2023 and the domination of the segment is expected to continue in the foreseen years. The adoption of cf-DNA is growing significantly among healthcare professionals and patients, primarily propelling segmental growth. In addition, the high accuracy of cf-DNA is another significant attribute promoting the growth rate of the NIPT market.

The FCMB segment is anticipated to showcase rapid growth during the forecast period. The high degree of accuracy of the FCMB method in detecting fetal abnormalities including chromosomal abnormalities is one of the major factors driving segmental growth. The non-invasiveness of FCMB and growing awareness among pregnant women and healthcare providers about the benefits of NIPT further boost the growth rate of the FCMB segment.

Global Non-Invasive Prenatal Testing Market - By Application:

  • Trisomy
  • Microdeletion
  • Genetics
  • Rh factor

Based on the application, the trisomy segment captured the leading share of the global NIPT market in 2023 and the segmental domination is anticipated to continue throughout the forecast period. The growing awareness regarding trisomy disorders among healthcare professionals and increasing preference towards early detection and management support segmental growth. The rising adoption of NIPT as a first-line screening test for trisomy by pregnant women and the growing emphasis of market players on developing novel NIPT products for trisomy detection further contribute to the segmental growth.

The microdeletion segment is anticipated to witness the fastest CAGR during the forecast period due to factors such as the growing prevalence of microdeletion disorders such as Prader-Willi syndrome, Angelman syndrome and Wolf-Hirschhorn syndrome and the high accuracy and reliability of NIPT in detecting microdeletions in the fetus.

Global Non-Invasive Prenatal Testing Market - By End-users:

  • Hospital
  • Diagnostic Labs

Based on end-user, the diagnostic lab's segment occupied the leading share of the NIPT market in 2023 and the domination of the segment is expected to continue during the forecast period. This is because the adoption of diagnostic labs is higher than the hospitals for NIPT. In addition, the domination of the segment can be credited to the availability of equipment and trained personnel required for NIPT among the diagnostic labs.

Non-Invasive Prenatal Testing Market - By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Geographically, North America had the largest share of the worldwide market in 2023 and the region's dominance is expected to continue during the forecast period. The popularity of NIPT has been increasing over the last several years. It is believed to be the first-line screening test for pregnant women, one of the key factors propelling the NIPT market in North America. In 2021, the U.S. NIPT market led North America, followed by Canada. The greater awareness among healthcare professionals and patients, growing adoption of technological developments, and increasing insurance coverage propel the NIPT market in the U.S. The growing number of U.S. initiatives further promotes the growth of the U.S. NIPT market. The U.S. government took numerous initiatives to promote awareness of prenatal and genetic testing. Furthermore, the growing maternal age is boosting the NIPT market in the U.S.

Europe had the second-largest regional share in the worldwide market in 2022 and is estimated to grow at a promising share during the forecast period. Factors such as increasing awareness regarding the NIPT, the growing number of NIPT procedures, rising adoption of non-invasive methods over invasive methods such as amniocentesis and increasing incidence of miscarriages propel the regional market growth. During the forecast period, the UK, Germany, France, and Spain are anticipated to hold a significant share of the European region. In addition, the availability of new and advanced NIPT technologies among European countries promotes the growth of the European NIPT market.

Asia-Pacific is anticipated to showcase the fastest CAGR during the forecast period owing to the growing population among the APAC countries such as India and China and the increasing usage of NIPT procedures. Furthermore, the number of pregnancies is growing significantly across the APAC region, favoring the APAC NIPT market growth. In addition, the rising incidence of genetic disorders is fuelling the NIPT market in the Asia-Pacific region. Furthermore, an increasing number of initiatives from the APAC governments in favor of NIPT and the availability of funding for R&D are promoting the growth of the NIPT market in the Asia-Pacific region.

During the forecast period, Latin America is estimated to have a steady share in the global market. The rising incidence of genetic diseases is a significant factor in regional market growth.

The Middle East and African market is expected to grow at a moderate share worldwide in the coming years.

KEY MARKET PARTICIPANTS:

Some of the most promising companies holding a significant share in the Global Non-Invasive Prenatal Testing Market profiled in this report are G.E. Healthcare (U.S.), Koninklijke Philips N.V. (Netherlands), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pacific Biosciences of California, Inc. (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (U.S.) and Beijing Genomics Institute (China).

RECENT DEVELOPMENTS IN THE MARKET:

  • In June 2019, Illumina, Inc. announced the launch of VeriSeq NIPT Solution v2, a CE-IVD NGS-based NIPT.
  • In November 2018, Perkin Elmer, Inc. announced the CE-mark approval for their Vanadis NIPT system for distribution and commercialization across the European region.
  • In June 2017, LifeCell partnered with LifeCodexx AG to provide rapid and affordable NIPT in India.

Please wait. . . . Your request is being processed

FAQ's

What was the size of the non-invasive prenatal testing market worldwide in 2021?

The global non-invasive prenatal testing market size was valued at USD 1.95 billion in 2021.

Which region had the largest share in the global non-invasive prenatal testing market in 2021?

North America had the largest share in the worldwide market in 2021, followed by Europe.

Which segment by instruments led the non-invasive prenatal testing market in 2021?

Based on instruments, the ultrasound segment occupied the major share of the non-invasive prenatal testing market in 2021.

What are the companies playing a noteworthy role in the non-invasive prenatal testing market?

G.E. Healthcare (U.S.), Koninklijke Philips N.V. (Netherlands), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pacific Biosciences of California, Inc. (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (U.S.) and Beijing Genomics Institute (China) are some of the major players in the non-invasive prenatal testing market.

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]